Key facts
- This page summarizes Nils Lonberg's Form 3 filing for Bicara Therapeutics Inc. (BCAX).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 12 Sep 2024, 21:03.
Nils Lonberg - 12 Sep 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)
- Reporting relationship
- Director
- Issuer ticker
- BCAX
- Reported as of
- 12 Sep 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 12 Sep 2024, 21:03:58 UTC
- Next SEC filing
- 10 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lara Meisner, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Nils Lonberg filed Form 3 for Bicara Therapeutics Inc. (BCAX) on 12 Sep 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCAX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 29,991
- Date
- 12 Sep 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BCAX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,125
- Exercise price
- $4.10
- Footnotes
- F1
BCAX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 12 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,159
- Exercise price
- $3.79
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares underlying this option vest in sixteen equal quarterly installments following November 8, 2021, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
The shares underlying this option vest in sixteen equal quarterly installments following September 22, 2023, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney